Loomis, Sayles & Company’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $181K | Sell |
7,500
-1,701
| -18% | -$44.5K | ﹤0.01% | 559 |
|
|
2026
Q1 | $258K | Buy |
9,201
+1,958
| +27% | +$52.1K | ﹤0.01% | 551 |
|
|
2025
Q4 | $180K | Sell |
7,243
-411
| -5% | -$10.4K | ﹤0.01% | 548 |
|
|
2025
Q3 | $195K | Sell |
7,654
-1,498
| -16% | -$37K | ﹤0.01% | 523 |
|
|
2025
Q2 | $222K | Buy |
9,152
+794
| +9% | +$18.5K | ﹤0.01% | 522 |
|
|
2025
Q1 | $212K | Buy |
8,358
+2,761
| +49% | +$72.2K | ﹤0.01% | 526 |
|
|
2024
Q4 | $148K | Sell |
5,597
-2,853
| -34% | -$77.4K | ﹤0.01% | 537 |
|
|
2024
Q3 | $245K | Buy |
8,450
+577
| +7% | +$16.8K | ﹤0.01% | 506 |
|
|
2024
Q2 | $220K | Sell |
7,873
-37
| -0.5% | -$1.02K | ﹤0.01% | 520 |
|
|
2024
Q1 | $220K | Sell |
7,910
-131
| -2% | -$3.63K | ﹤0.01% | 515 |
|
|
2023
Q4 | $232K | Sell |
8,041
-715
| -8% | -$21.6K | ﹤0.01% | 497 |
|
|
2023
Q3 | $290K | Sell |
8,756
-10,937
| -56% | -$387K | ﹤0.01% | 488 |
|
|
2023
Q2 | $722K | Sell |
19,693
-850
| -4% | -$33.1K | ﹤0.01% | 462 |
|
|
2023
Q1 | $838K | Sell |
20,543
-5,833
| -22% | -$252K | ﹤0.01% | 456 |
|
|
2022
Q4 | $1.35M | Buy |
26,376
+10,797
| +69% | +$518K | ﹤0.01% | 422 |
|
|
2022
Q3 | $682K | Buy |
15,579
+7,679
| +97% | +$373K | ﹤0.01% | 421 |
|
|
2022
Q2 | $414K | Sell |
7,900
-18,454
| -70% | -$940K | ﹤0.01% | 459 |
|
|
2022
Q1 | $1.36M | Sell |
26,354
-7,344
| -22% | -$381K | ﹤0.01% | 441 |
|
|
2021
Q4 | $1.99M | Sell |
33,698
-7,023
| -17% | -$348K | ﹤0.01% | 453 |
|
|
2021
Q3 | $1.75M | Sell |
40,721
-4,719
| -10% | -$209K | ﹤0.01% | 466 |
|
|
2021
Q2 | $1.78M | Buy |
45,440
+3,270
| +8% | +$127K | ﹤0.01% | 463 |
|
|
2021
Q1 | $1.53M | Buy |
42,170
+41,094
| +3,819% | +$1.46M | ﹤0.01% | 468 |
|
|
2020
Q4 | $40K | Sell |
1,076
-5,742
| -84% | -$211K | ﹤0.01% | 560 |
|
|
2020
Q3 | $237K | Sell |
6,818
-1,803
| -21% | -$63.2K | ﹤0.01% | 500 |
|
|
2020
Q2 | $267K | Sell |
8,621
-12,811
| -60% | -$435K | ﹤0.01% | 495 |
|
|
2020
Q1 | $664K | Sell |
21,432
-45,915
| -68% | -$1.56M | ﹤0.01% | 481 |
|
|
2019
Q4 | $2.5M | Buy |
67,347
+58,171
| +634% | +$2.07M | ﹤0.01% | 426 |
|
|
2019
Q3 | $313K | Sell |
9,176
-114,282
| -93% | -$4.16M | ﹤0.01% | 503 |
|
|
2019
Q2 | $5.07M | Buy |
+123,458
| New | +$4.9M | 0.01% | 404 |
|
|
2019
Q1 | – | Sell |
-7,647
| Closed | -$317K | – | 849 |
|
|
2018
Q4 | $317K | Sell |
7,647
-82,933
| -92% | -$3.44M | ﹤0.01% | 567 |
|
|
2018
Q3 | $3.79M | Sell |
90,580
-300,848
| -77% | -$11.6M | 0.01% | 501 |
|
|
2018
Q2 | $13.5M | Sell |
391,428
-266,190
| -40% | -$9.1M | 0.03% | 343 |
|
|
2018
Q1 | $22.1M | Sell |
657,618
-1,228,058
| -65% | -$42.2M | 0.05% | 216 |
|
|
2017
Q4 | $64.8M | Sell |
1,885,676
-949,412
| -33% | -$32.4M | 0.13% | 71 |
|
|
2017
Q3 | $96M | Sell |
2,835,088
-301,889
| -10% | -$9.7M | 0.21% | 52 |
|
|
2017
Q2 | $100M | Sell |
3,136,977
-161,637
| -5% | -$5.1M | 0.24% | 46 |
|
|
2017
Q1 | $107M | Buy |
3,298,614
+194,667
| +6% | +$6.14M | 0.27% | 47 |
|
|
2016
Q4 | $95.7M | Sell |
3,103,947
-287,891
| -8% | -$8.79M | 0.23% | 57 |
|
|
2016
Q3 | $109M | Sell |
3,391,838
-141,386
| -4% | -$4.73M | 0.28% | 46 |
|
|
2016
Q2 | $118M | Buy |
3,533,224
+313,504
| +10% | +$10M | 0.32% | 42 |
|
|
2016
Q1 | $90.5M | Buy |
3,219,720
+765,420
| +31% | +$21.9M | 0.26% | 52 |
|
|
2015
Q4 | $75.2M | Sell |
2,454,300
-204,149
| -8% | -$6.42M | 0.21% | 63 |
|
|
2015
Q3 | $79.2M | Sell |
2,658,449
-371,929
| -12% | -$11.9M | 0.23% | 65 |
|
|
2015
Q2 | $96.4M | Sell |
3,030,378
-322,089
| -10% | -$10.5M | 0.26% | 66 |
|
|
2015
Q1 | $111M | Sell |
3,352,467
-530,335
| -14% | -$16.9M | 0.31% | 61 |
|
|
2014
Q4 | $115M | Sell |
3,882,802
-472,064
| -11% | -$13.5M | 0.32% | 54 |
|
|
2014
Q3 | $122M | Sell |
4,354,866
-9,601
| -0.2% | -$269K | 0.36% | 54 |
|
|
2014
Q2 | $123M | Sell |
4,364,467
-970,131
| -18% | -$27.7M | 0.35% | 62 |
|
|
2014
Q1 | $163M | Sell |
5,334,598
-191,843
| -3% | -$5.72M | 0.46% | 49 |
|
|
2013
Q4 | $161M | Buy |
5,526,441
+86,012
| +2% | +$2.5M | 0.48% | 42 |
|
|
2013
Q3 | $148M | Sell |
5,440,429
-1,146,188
| -17% | -$31.2M | 0.48% | 40 |
|
|
2013
Q2 | $175M | Buy |
+6,586,617
| New | +$182M | 0.62% | 26 |
|
Other funds holding PFE
Loomis, Sayles & Company's PFE Position: Q2 2026 in Review
Loomis, Sayles & Company reduced its Pfizer (PFE) stake by 18% in Q2 2026, selling an estimated $44.5K and leaving 7,500 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #559.
Loomis, Sayles & Company first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $175M in Q2 2013. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Loomis, Sayles & Company held 7,500 shares of Pfizer worth $181K as of Q2 2026.
- Loomis, Sayles & Company sold 1,701 Pfizer shares in Q2 2026, an estimated $44.5K.
- Pfizer made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #559 holding.
- Loomis, Sayles & Company first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Loomis, Sayles & Company's Pfizer position peaked at $175M in Q2 2013.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.